Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?

Szczegóły
Abstrakt

Tytuł:: Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
Autorzy:: Huebner NA; Department of Urology, Medical University of Vienna, Vienna, Austria.; Working Group for Diagnostic imaging in Urology (ABDU), Austrian association of Urology (ÖGU), Vienna, Austria.
Korn S; Department of Urology, Medical University of Vienna, Vienna, Austria.
Resch I; Department of Urology, Medical University of Vienna, Vienna, Austria.
Grubmüller B; Department of Urology, Medical University of Vienna, Vienna, Austria.
Gross T; Department of Urology, Medical University of Vienna, Vienna, Austria.
Gale R; Department of Urology, Medical University of Vienna, Vienna, Austria.
Kramer G; Department of Urology, Medical University of Vienna, Vienna, Austria.
Poetsch N; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20 1090, Vienna, Austria.
Clauser P; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20 1090, Vienna, Austria.
Haitel A; Department of Pathology, Medical University of Vienna, Vienna, Austria.
Fajkovic H; Department of Urology, Medical University of Vienna, Vienna, Austria.; Working Group for Diagnostic imaging in Urology (ABDU), Austrian association of Urology (ÖGU), Vienna, Austria.; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria.; Division of Urology, Department of Urology, University of Jordan, Amman, Jordan.; Institute of Urology and Reproductive Health, Sechenov University, Moscow, Russia.; Department of Urology, Weill Cornell Medical Centre, New York, USA.; Department of Urology, University of Texas Southwestern, Dallas, USA.
Baltzer PA; Working Group for Diagnostic imaging in Urology (ABDU), Austrian association of Urology (ÖGU), Vienna, Austria. .; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20 1090, Vienna, Austria. .
Źródło:: European radiology [Eur Radiol] 2021 Jun; Vol. 31 (6), pp. 3754-3764. Date of Electronic Publication: 2020 Dec 02.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Berlin : Springer International, c1991-
MeSH Terms:: Multiparametric Magnetic Resonance Imaging*
Prostatic Neoplasms*/diagnostic imaging
Contrast Media ; Diffusion Magnetic Resonance Imaging ; Humans ; Magnetic Resonance Imaging ; Male ; Retrospective Studies
References:: Richenberg J, Løgager V, Panebianco V, Rouviere O, Villeirs G, Schoots IG (2019) The primacy of multiparametric MRI in men with suspected prostate cancer. Eur Radiol 29(12):6940–6952. (PMID: 10.1007/s00330-019-06166-z)
Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815–822. (PMID: 10.1016/S0140-6736(16)32401-1)
Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777. (PMID: 10.1056/NEJMoa1801993)
Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. (PMID: 10.1016/j.eururo.2016.08.003)
Boesen L, Norgaard N, Logager V et al (2018) Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Netw Open 1(2):e180219. (PMID: 10.1001/jamanetworkopen.2018.0219)
Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76(3):340–351. (PMID: 10.1016/j.eururo.2019.02.033)
Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137. (PMID: 10.1016/j.eururo.2013.09.046)
Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH (2018) Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 211(5):W226–W241. (PMID: 10.2214/AJR.18.19880)
Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 69(1):16–40. (PMID: 10.1016/j.eururo.2015.08.052)
de Rooij M, Israël B, Tummers M et al (2020) ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radiol 30(10):5404–5416.
Bath M, Mansson LG (2007) Visual grading characteristics (VGC) analysis: a non-parametric rank-invariant statistical method for image quality evaluation. Br J Radiol 80(951):169–176. (PMID: 10.1259/bjr/35012658)
Vargas HA, Hotker AM, Goldman DA et al (2016) Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol 26(6):1606–1612. (PMID: 10.1007/s00330-015-4015-6)
Brembilla G, Dell’Oglio P, Stabile A et al (2020) Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1. Eur Radiol 30(6):3383–3392.
Girometti R, Giannarini G, Greco F et al (2019) Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: a study using whole-mount histology as the standard of reference. J Magn Reson Imaging 49(2):546–555. (PMID: 10.1002/jmri.26220)
Polanec S, Helbich TH, Bickel H et al (2016) Head-to-head comparison of PI-RADS v2 and PI-RADS v1. Eur J Radiol 85(6):1125–1131. (PMID: 10.1016/j.ejrad.2016.03.025)
Krishna S, McInnes M, Lim C et al (2017) Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the detection of peripheral zone Gleason score 3 + 4 = 7 cancers. AJR Am J Roentgenol 209(6):W365–W373. (PMID: 10.2214/AJR.17.17964)
Stabile A, Giganti F, Kasivisvanathan V et al (2020) Factors influencing variability in the performance of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer: a systematic literature review. Eur Urol Oncol 3(2):145–167. (PMID: 10.1016/j.euo.2020.02.005)
Moldovan PC, Van den Broeck T, Sylvester R et al (2017) What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol 72(2):250–266. (PMID: 10.1016/j.eururo.2017.02.026)
van der Leest M, Cornel E, Israel B et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75(4):570–578. (PMID: 10.1016/j.eururo.2018.11.023)
Borofsky S, George AK, Gaur S et al (2018) What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology 286(1):186–195. (PMID: 10.1148/radiol.2017152877)
Jambor I, Bostrom PJ, Taimen P et al (2017) Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging 46(4):1089–1095. (PMID: 10.1002/jmri.25641)
Rischmann P, Gelet A, Riche B et al (2017) Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 71(2):267–273. (PMID: 10.1016/j.eururo.2016.09.039)
Scheltema MJ, Chang JI, Bohm M et al (2018) (2018) Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol 36(9):1383–1389. https://doi.org/10.1007/s00345-018-2281-z. (PMID: 10.1007/s00345-018-2281-z295945516105143)
Salari K, Kuppermann D, Preston MA et al (2019) Active surveillance of prostate cancer is a viable option for men younger than 60 years. J Urol 201(4):721–727. (PMID: 10.1097/JU.0000000000000031)
Musunuru HB, Yamamoto T, Klotz L et al (2016) Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol 196(6):1651–1658. (PMID: 10.1016/j.juro.2016.06.102)
van den Bos W, Muller BG, Ahmed H et al (2014) Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 65(6):1078–1083. (PMID: 10.1016/j.eururo.2014.01.001)
De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM (2010) Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 194(6):1427–1433. (PMID: 10.2214/AJR.10.4263)
Sanguedolce F, Petralia G, Sokhi H et al (2018) Baseline multiparametric MRI for selection of prostate cancer patients suitable for active surveillance: which features matter? Clin Genitourin Cancer 16(2):155–163.e6. (PMID: 10.1016/j.clgc.2017.10.020)
Wibulpolprasert P, Raman SS, Hsu W et al (2020) Influence of the location and zone of tumor in prostate cancer detection and localization on 3-T multiparametric MRI based on PI-RADS Version 2. AJR Am J Roentgenol 1–11. https://doi.org/10.2214/AJR.19.21608.
Clauser P, Pinker K, Helbich TH, Kapetas P, Bernathova M, Baltzer PAT (2014) Fat saturation in dynamic breast MRI at 3 Tesla: is the Dixon technique superior to spectral fat saturation? A visual grading characteristics study. Eur Radiol 24(9):2213–2219. (PMID: 10.1007/s00330-014-3189-7)
Polanec SH, Lazar M, Wengert GJ et al (2018) 3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. Eur Radiol 28(4):1634–1641. (PMID: 10.1007/s00330-017-5120-5)
Contributed Indexing:: Keywords: AUC; Clinical decision-making; Diffusion MRI; Prostate cancer; mpMRI
Substance Nomenclature:: 0 (Contrast Media)
Entry Date(s):: Date Created: 20201202 Date Completed: 20210520 Latest Revision: 20210623
Update Code:: 20240105
PubMed Central ID:: PMC8128749
DOI:: 10.1007/s00330-020-07494-1
PMID:: 33263793
: Czasopismo naukowe

Full Text Finder

Objectives: To assess the visibility of clinically significant prostate cancer (PCA) lesions on the sequences multiparametric MRI of the prostate (mpMRI) and to evaluate whether the addition of dynamic contrast-enhanced imaging (DCE) improves the overall visibility.
Methods: We retrospectively evaluated multiparametric MRI images of 119 lesions in 111 patients with biopsy-proven clinically significant PCA. Three readers assigned visual grading scores for visibility on each sequence, and a visual grading characteristic analysis was performed. Linear regression was used to explore which factors contributed to visibility in individual sequences.
Results: The visibility of lesions was significantly better with mpMRI when compared to biparametric MRI in visual grading characteristic (VGC) analysis, with an AUC VGC of 0.62 (95% CI 0.55-0.69; p < 0.001). This benefit was seen across all readers. Multivariable linear regression revealed that a location in the peripheral zone was associated with better visibility on T2-weighted imaging (T2w). A higher Prostate Imaging-Reporting and Data System (PI-RADS) score was associated with better visibility on both diffusion-weighted imaging (DWI) and DCE. Increased lesion size was associated with better visibility on all sequences.
Conclusions: Visibility of clinically significant PCA is improved by using mpMRI. DCE and DWI images independently improve lesion visibility compared to T2w images alone. Further research into the potential of DCE to impact on clinical decision-making is suggested.
Key Points: • DCE and DWI images independently improve clinically significant prostate cancer lesion visibility compared to T2w images alone. • Multiparametric MRI (DCE, DWI, T2w) achieved significantly higher visibility scores than biparametric MRI (DWI, T2w). • Location in the transition zone is associated with poor visibility on T2w, while it did not affect visibility on DWI or DCE.

Informacja